In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: In vivo radiopharmaceuticals

This article was originally published in The Gray Sheet

Executive Summary

In vivo radiopharmaceuticals: FDA will hold a public meeting Feb. 27 on developing regulations on the use of in vivo radiopharmaceuticals diagnosis and monitoring. The agency will be soliciting input from patient advocacy groups, physicians, industry and the public concerning the development of new regulations for the review of radiopharmaceutical applications as required by the FDA Modernization Act. Written comments are due March 4. The meeting will begin at 8:00 a.m. in Conference Rooms D and E of FDA's Parklawn building in Rockville, Maryland...

You may also be interested in...

Fosun’s IPO Plan For India’s Gland Hits Multiple Targets

With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.

China Provides Patent Linkage In Latest Law Draft - Why Now?

In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.

QUOTED. 15 July 2020. Michael Herzog.

Hedge fund Davidson Kempner is recommending that Qiagen NV renegotiate its planned takeover deal with Thermo Fisher Scientific, arguing that demand for diagnostic fueled by the COVID-19 pandemic makes Qiagen worth more than the price agreed on in March. See what Davidson Kempner’s partner Michael Herzog said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts